In the CREATE-X trial, patients with hormone receptor–positive breast cancer were allowed concomitant adjuvant hormonal therapy while on capecitabine, a departure from the usual approach of not combining hormonal therapy and chemotherapy, and this represents a limitation of the study. Here, NR4A1 is linked to breast cancer.